RxDoctor Payments Data

Steven Beenstock, DO

Family Medicine · Newark, NJNPI 1043250707

Payments from drug & device makers

$1,127in general payments, 2019–2025

Across 22 payments — averaging $51.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$655
  • AstraZeneca$171
  • Otsuka America Pharmaceutical, Inc.$125
  • Exact Sciences$39
  • Pfizer$30
  • Teleflex LLC$28
  • plus $79 from 6 others

What the payments were for

  • Food & beverage$1,11699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,127 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,979
Medicare patients
368
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$195,719
JanuviaSitagliptin Phosphate48$74,176
FarxigaDapagliflozin Propanediol42$48,433
JardianceEmpagliflozin31$48,320
TrulicityDulaglutide32$33,424
EliquisApixaban35$33,352
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$21,875
XareltoRivaroxaban15$14,286
TradjentaLinagliptin16$10,381
Rosuvastatin Calcium579$8,898
Repatha SureclickEvolocumab11$6,086
SymbicortBudesonide/Formoterol Fumarate14$5,179
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,099
Atorvastatin Calcium419$4,331
Valsartan140$4,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$195,719141 claims
MerckJanuvia$11$74,17648 claims
Boehringer IngelheimJardiance, Tradjenta$14$58,70147 claims
AstraZenecaFarxiga, Symbicort$171$53,61256 claims
PfizerEliquis$30$33,35235 claims
GSKAnoro Ellipta$14$21,87543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →